Search

Your search keyword '"X Vinolas Prat"' showing total 2 results
Start Over Author "X Vinolas Prat" Publication Year Range Last 3 years
2 results on '"X Vinolas Prat"'

1. Clinical features of drug-induced long QT syndrome in a large prospective cohort

Author

B Campos Garcia, H Hernandez-Ontiveros, A Avila-Parcet, V Garcia-Hernando, M Carceller-Sindreu, J Salazar-Blanco, B Rodriguez-Santiago, A Juanes-Borrego, C Alonso-Martin, E Rodriguez-Font, Z Moreno-Weidmann, F Mendez-Zurita, X Vinolas-Prat, and J M Guerra Ramos

Subjects
Cardiology and Cardiovascular Medicine
Abstract

Introduction Drug-induced long QT syndrome (DI-LQTS) is a clinical entity with prevalence and arrhythmic risk not well defined. Purpose To determine the clinical characteristics of patients with DI-LQTS diagnosed in the setting of a tertiary hospital center. Methods Prospective observational study with consecutive inclusion of patients with the diagnosis of DI-LQTS as per standard criteria, in a tertiary hospital, between 2018 and 2022. Results Eighty-five patients were included (age 65±15 years, 59% male). The mean corrected QT interval (QTc) of the entire cohort was 545±56 ms. The drugs responsible for QTc prolongation were: psychotropic drugs 51%, antiarrhythmics 38%, anesthetics 29%, antibiotics 15%, antineoplastics 3%, other 2%. QTc prolongation was due to the combination of ≥2 responsible drugs in 46 (54%) patients, and to the use of a single drug in 39 (46%). Twenty-one patients (25%) presented ventricular arrhythmias at the time of drug-induced QT prolongation: 10 (12%) ventricular fibrillation, 7 (8%) sustained ventricular tachycardia, 3 (3%) non-sustained ventricular tachycardia, 1 (1%) frequent ventricular extrasystole. Patients with ventricular arrhythmias were older (73±12 vs 62±15 years, p Conclusion The DI-LQTS is a rare clinical entity but may be cause of clinically-relevant ventricular arrhythmias. Older age and greater prolongation of the QTc interval are associated with an increased risk of ventricular arrhythmic events. Funding Acknowledgement Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Health Institute Carlos III, Spain

Published
2022
Full Text
View/download PDF

2. Leadless pacemakers at 5-year follow-up: the Micra transcatheter pacing system post-approval registry.

Author

El-Chami MF, Garweg C, Clementy N, Al-Samadi F, Iacopino S, Martinez-Sande JL, Roberts PR, Tondo C, Johansen JB, Vinolas-Prat X, Cha YM, Grubman E, Bordachar P, Stromberg K, Fagan DH, and Piccini JP

Subjects
Humans, Treatment Outcome, Equipment Design, Registries, Cardiac Pacing, Artificial adverse effects, Arrhythmias, Cardiac therapy, Arrhythmias, Cardiac etiology, Pacemaker, Artificial adverse effects
Abstract

Background and Aims: Prior reports have demonstrated a favourable safety and efficacy profile of the Micra leadless pacemaker over mid-term follow-up; however, long-term outcomes in real-world clinical practice remain unknown. Updated performance of the Micra VR leadless pacemaker through five years from the worldwide post-approval registry (PAR) was assessed., Methods: All Micra PAR patients undergoing implant attempts were included. Endpoints included system- or procedure-related major complications and system revision rate for any cause through 60 months post-implant. Rates were compared through 36 months post-implant to a reference dataset of 2667 transvenous pacemaker patients using Fine-Gray competing risk models., Results: 1809 patients were enrolled between July 2015 and March 2018 and underwent implant attempts from 179 centres in 23 countries with a median follow-up period of 51.1 months (IQR: 21.6-64.2). The major complication rate at 60 months was 4.5% [95% confidence interval (CI): 3.6%-5.5%] and was 4.1% at 36 months, which was significantly lower than the 8.5% rate observed for transvenous systems (HR: .47, 95% CI: .36-.61; P < .001). The all-cause system revision rate at 60 months was 4.9% (95% CI: 3.9%-6.1%). System revisions among Micra patients were mostly for device upgrades (41.2%) or elevated thresholds (30.6%). There were no Micra removals due to infection noted over the duration of follow-up. At 36 months, the system revision rate was significantly lower with Micra vs. transvenous systems (3.2% vs. 6.6%, P < .001)., Conclusions: Long-term outcomes with the Micra leadless pacemaker continue to demonstrate low rates of major complications and system revisions and an extremely low incidence of infection., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results